Get the Stockscreener App
26.19
1.95%
-0.5301
Kiniksa Pharmaceuticals International Plc stock is traded at $26.19, with a volume of 138.89K.
It is down -1.95% in the last 24 hours and up +31.66% over the past month.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
See More
Previous Close:
$26.72
Open:
$26.86
24h Volume:
138.89K
Relative Volume:
0.22
Market Cap:
$2.02B
Revenue:
$384.10M
Net Income/Loss:
$-9.07M
P/E Ratio:
-187.07
EPS:
-0.14
Net Cash Flow:
$11.10M
1W Performance:
-5.24%
1M Performance:
+31.66%
6M Performance:
+14.61%
1Y Performance:
+29.77%
1-Day Range:
$26.15
$27.14
1-Week Range:
$25.97
$28.56
52-Week Range:
$17.38
$28.56
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals International Plc
Sector
Phone
(781) 431-9100
Address
23 OLD BOND STREET, FLOOR 3, LONDON
Compare KNSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
26.18 | 2.02B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
160.36 | 69.43B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 47.30B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.77 | 46.56B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.00 | 20.71B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
303.72 | 13.25B | 2.76B | 1.11B | 898.10M | 22.77 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| May-03-24 | Initiated | Wells Fargo | Overweight |
| Jun-29-20 | Reiterated | BofA Securities | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Dec-12-18 | Reiterated | Wedbush | Outperform |
| Jun-19-18 | Initiated | JMP Securities | Mkt Outperform |
View All
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News
Kiniksa Pharmaceuticals: Making Steady Progress (NASDAQ:KNSA) - Seeking Alpha
Insider’s View: Deciphering Kiniksa Pharmaceuticals International Plc (KNSA)’s Financial Health Through Ratios - DWinneX
How should investors view Kiniksa Pharmaceuticals International Plc (KNSA)? - uspostnews.com
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,265,339, According to a Recent SEC Filing - marketscreener.com
Kiniksa Pharmaceuticals Executives Sell Shares - TradingView
Wall Street analysts’ outlook for Kiniksa Pharmaceuticals International Plc (KNSA) - Sete News
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2025 Earnings Call Transcript - Insider Monkey
3 Stocks Including Kiniksa Pharmaceuticals International That May Be Priced Below Intrinsic Value Estimates - Yahoo Finance
Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025: Everyt - GuruFocus
Examining the Potential Price Growth of Kiniksa Pharmaceuticals International Plc (KNSA) - knoxdaily.com
Kiniksa (KNSA) Partners with Carly Pearce for Health Awareness C - GuruFocus
Kiniksa (KNSA) Partners with Carly Pearce for Health Awareness Campaign | KNSA Stock News - GuruFocus
Kiniksa Pharmaceuticals International Plc (KNSA) Stock: A Year of Decreases and Increases - investchronicle.com
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis - GlobeNewswire
Country Star Carly Pearce Opens Up About 4-Year Struggle With Rare Heart Disease in New Campaign - Stock Titan
An Intrinsic Calculation For Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Suggests It's 41% Undervalued - Yahoo Finance
Kiniksa raises ARCALYST 2025 revenue guidance to $605M amid strong Q1 performance - msn.com
Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus
Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $36 From $34, Maintains Outperform Rating - marketscreener.com
Kiniksa Pharmaceuticals: A Biotech Stock on the Rise, But What’s Next? - RagingBull
Kiniksa Pharmaceuticals International, plc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Kiniksa Pharmaceuticals Surpasses Q1 2025 Revenue Estimates with $137.8 Million, EPS Details Unavailable - GuruFocus
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Res - GuruFocus
KNSA Reports Strong Q1 Revenue and Updates ARCALYST Sales Foreca - GuruFocus
Kiniksa Pharmaceuticals Swings to Q1 Net Income, Revenue Increases - marketscreener.com
KNSA: Kiniksa Forecasts Increased ARCALYST Revenue for 2025 | KN - GuruFocus
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution - The Manila Times
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results - TradingView
Earnings Flash (KNSA) Kiniksa Pharmaceuticals International Posts Q1 EPS $0.11, vs. FactSet Est of $0.13 per Share - marketscreener.com
Kiniksa Q1 Earnings: ARCALYST Revenue Soars 75% to $138M, 2025 Guidance Boosted to $605M - Stock Titan
Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook - Benzinga
Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 - GlobeNewswire
Kiniksa Pharmaceuticals Sets Q1 2025 Earnings Call Date: How to Access Live Results and Portfolio Updates - Stock Titan
Its Stock Has Paid Off Big Time For Kiniksa Pharmaceuticals International Plc - Sete News
Kiniksa Pharmaceuticals introduces new incentive plan By Investing.com - Investing.com India
Kiniksa Pharmaceuticals introduces new incentive plan - Investing.com Australia
Kiniksa Pharmaceuticals chief commercial officer sells $370,475 in stock By Investing.com - Investing.com South Africa
Kiniksa Pharmaceuticals chief commercial officer sells $370,475 in stock - Investing.com Australia
Lacklustre Performance Is Driving Kiniksa Pharmaceuticals International, plc's (NASDAQ:KNSA) Low P/S - simplywall.st
SEC Form DEFA14A filed by Kiniksa Pharmaceuticals International plc - Quantisnow
Analysts Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) PT at $37.17 - Defense World
KNSA Stock Sees Decline of Approximately -1.89% in Last Five Days - knoxdaily.com
Kiniksa CFO Mark Ragosa sells shares worth $368,465 By Investing.com - Investing.com South Africa
Kiniksa CFO Mark Ragosa sells shares worth $368,465 - Investing.com India
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Down 1.8 - GuruFocus
Kiniksa pharmaceuticals CFO Mark Ragosa sells $469,923 in stock By Investing.com - Investing.com South Africa
Kiniksa pharmaceuticals CFO Mark Ragosa sells $469,923 in stock - Investing.com
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):